首页> 外文OA文献 >Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

【2h】

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

机译：靶向17 Q23扩增子以克服HER2 +乳腺癌抗HER2治疗的抵抗力

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yunhua Liu; Jiangsheng Xu; Hyun Ho Choi; Cecil Han; Yuanzhang Fang; Yujing Li; Kevin Van der Jeught; Hanchen Xu; Lu Zhang; Michael Frieden; Lifei Wang; Haniyeh Eyvani; Yifan Sun; Gang Zhao; Yuntian Zhang; Sheng Liu; Jun Wan; Cheng Huang; Guang Ji; Xiongbin Lu; Xiaoming He; Xinna Zhang;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer [J] . Yunhua Liu, Jiangsheng Xu, Hyun Ho Choi, Nature Communications . 2018,第1期

机译：靶向17q23扩增子以克服对HER2 +乳腺癌的抗HER2治疗的耐药性
2. A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：用Letrozole的新辅助试验鉴定了17 Q23扩增子的PRR11，作为ER阳性乳腺癌抗内分泌治疗的机制
3. A SYSTEMS PHARMACOLOGY MODEL TO EVALUATE TRIPLE DRUG COMBINATION THERAPY AT OVERCOMING RESISTANCE TO ANTI-HER2 THERAPY IN HER2-POSITIVE BREAST CANCER. [J] . Franco Y., Ramakrishnan V., Vaidya T., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：一种系统药理学模型，评价三重药物联合治疗在耐乳癌抗Her2疗法耐抗Her2疗法中的抗性。
4. Preparation and Characterization of PE38KDEL-Loaded anti-HER2 modified nanoparticles for targeted cancer therapy [C] . LI Zhong, rnCHEN Haiming, rnSUN Fuxue, Novel Drug Delivery Systems: Research and Application . 2007

机译：载有PE38KDEL的抗HER2修饰纳米粒的制备及表征
5. Overcoming Anti-Estrogen Resistance in Estrogen Receptor (ER)-Positive Breast Cancer: Rational Targeting of Phosphatidylinositol 3-Kinase (PI3K) and the Resurrection of Estrogen Therapy [D] . Hosford, Sarah 2018

机译：克服雌激素受体（ER）阳性乳腺癌中的抗雌激素抵抗：磷脂酰肌醇3-激酶（PI3K）的合理靶向和雌激素疗法的复活
6. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer [O] . Yunhua Liu, Jiangsheng Xu, Hyun Ho Choi, -1

机译：靶向17q23扩增子以克服对HER2 +乳腺癌的抗HER2治疗的耐药性
7. Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer? [O] . Florian Huemer, Simon Peter Gampenrieder, Alexander Schlattau, 2014

机译：在第五线疗法中克服Her2靶向剂的抵抗力：在HER2 +乳腺癌中仍然存在贝伐单抗的地方吗？

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅